Private Advisor Group LLC acquired a new position in SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH – Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 55,777 shares of the company’s stock, valued at approximately $3,017,000.
Several other institutional investors also recently modified their holdings of the company. Advisory Services Network LLC bought a new stake in shares of SPDR S&P Pharmaceuticals ETF during the third quarter valued at approximately $34,000. Team Financial Group LLC acquired a new stake in SPDR S&P Pharmaceuticals ETF during the fourth quarter worth $56,000. Kestra Advisory Services LLC bought a new stake in SPDR S&P Pharmaceuticals ETF in the 4th quarter valued at $151,000. Vista Investment Management bought a new stake in SPDR S&P Pharmaceuticals ETF in the 4th quarter valued at $223,000. Finally, Stephens Inc. AR acquired a new position in shares of SPDR S&P Pharmaceuticals ETF in the 4th quarter valued at $229,000.
SPDR S&P Pharmaceuticals ETF Stock Performance
NYSEARCA:XPH opened at $70.05 on Friday. The company has a 50-day moving average of $60.61 and a 200-day moving average of $57.66. The company has a market capitalization of $458.83 million, a price-to-earnings ratio of 14.28 and a beta of 0.58. SPDR S&P Pharmaceuticals ETF has a 52 week low of $40.80 and a 52 week high of $70.15.
SPDR S&P Pharmaceuticals ETF Company Profile
SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Read More
- Five stocks we like better than SPDR S&P Pharmaceuticals ETF
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Want to see what other hedge funds are holding XPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH – Free Report).
Receive News & Ratings for SPDR S&P Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
